<DOC>
	<DOC>NCT02672436</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.</brief_summary>
	<brief_title>ENERGI-F703 for Diabetic Foot Ulcers Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1. With either gender aged at least 20 years old 2. With diabetic mellitus (DM; currently under DM medication treatment or na√Øve DM subject with duplicated HbA1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least one week apart before Screening) 3. With at least one cutaneous ulcer on the foot (including ulcers on the lower legs) and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If two or more ulcers have the largest size, the one with worst grade will be selected. If two or more ulcers have the largest size and grade, the one with longest duration will be selected. 4. The target ulcer is classified as grade 1 to 3 ulcer according to Wagner Grading System and with ulcer size of 1 cm2 to 50 cm2 (Grade 3 ulcer subject may enter the study only if after debridement, the abscess of target ulcer is under control at investigator's discretion and osteomyelitis does not present) 5. Subject should be free of any necrosis or infection in soft and bone tissue; 6. Subject has signed the written informed consent form 1. With active osteomyelitis 2. With target ulcer size decreased by at least 30% after at least 2 weeks of standardofcareonly period or any other recorded regular therapy before Randomization visit 3. With poor nutritional status (albumin &lt; 2g/dl), poor diabetic control (HbA1c &gt; 12%), a leukocyte counts &lt; 2,000/mm3, abnormal liver function (AST, ALT&gt;3 x upper limit of normal range) 4. Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents 5. With known or suspected hypersensitivity to any ingredients of study product and vehicle 6. With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study 7. Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period 8. Enrollment in any investigational drug trial within 4 weeks before entering this study 9. With any condition judged by the investigator that entering the trial may be detrimental to the subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Wound Healing</keyword>
</DOC>